December 4-6, 2018

Boston, MA

Join the 4th Annual OV SUMMIT

Boston, MA - December 4-6 2018

The 4th Oncolytic Virotherapy Summit is dedicated to improving the commercial success of oncolytic viruses, in stand-alone and combination therapies.

As many oncolytic viruses progress through the clinical pipelines, drug developers need to ensure that their therapies are safe, efficacious and commercially viable. Make sure you stay ahead of the game and join Oncolytic Virotherapy Summit, where you will have an opportunity to pick the brains of 100+ senior industry peers and tackle your challenges in discovery, clinical development, manufacturing and regulations of oncolytic virotherapy.

This year we will be incorporating commercial insights from companies such as Amgen, Pfizer, Merck, Replimune, Targovax, DNAtrix, Vyriad, Virogin and many more, which will allow you to learn from their case studies and improve your development strategies. Participate in the interactive roundtable and workshops to build strategies that maximise success in the clinic and commercially. Want to know more?

PAST ATTENDEE PROFILE

%

OF PAST ATTENDEES WERE DIRECTOR LEVEL AND ABOVE

%

OF PAST ATTENDEES WERE DRUG DEVELOPERS

%

OF PAST ATTENDEES FIND OV SUMMIT AS A VALUABLE EXPERIENCE FOR THEIR BUSINESS/CAREER

"The best thing about the OV Summit is that it is so small and focused. Every single presentation was very interesting and relevant, every chance meeting at the networking breaks led to an interesting conversation. I hope this event will stay that way! Small and hyper-focused!"

2017 Attendee

"The Oncolytic Virotherapy Summit in Miami 2017 was a great experience - the spirit of Pharma and Biotech to help and help or cure patients with terminal disease is clearly very prominent in this community. "

2017 Attendee

“The Oncolytic Virotherapy Summit is an awesome opportunity to network, to learn what has been happening in the OV field and also what to expect in the future.”

Past Attendee from Boehringer Ingelheim

“Excellent meeting with substantive content.”

Past Attendee from Tocagen Inc.

"First participation to this meeting. I am new to this industry. I found the talks interesting and on focus. The small size of the meeting is an asset for that matter."

2017 Attendee

MEET AND LEARN FROM:

Robert Coffin

Robert Coffin
Chief Executive Officer
Replimune

Rachel Altura

Rachel Altura
Senior Medical Director
Merck & Co.

Magnus Jaderberg

Magnus Jaderberg
Chief Medical Officer
Targovax

Anna Cascante

Anna Cascante
Head of R&D
Sagetis Biotech

REASONS TO CHOOSE ONCOLYTIC VIROTHERAPIES SUMMIT 2018:

1. Previously unseen showcase of systemic delivery approaches for more cost-effective OVs

2. Assessments of various payloads to generate the right immune response

3. Clinical updates on combination trials to establish more opportunities for OVs

AGENDA HIGHLIGHTS - NEW FOR 2018

PRE-CONFERENCE WORKSHOP DAY

Panel style workshop allowing biotech and pharma attendees to explore how OVs could fit within a broad oncology drug portfolio, ultimately maximising the therapeutic and commercial value of OVs.

R&D, Clinical Development & GMP Manufacturing of Oncolytic Viruses in China

Hear the story of how the first oncolytic virus, Oncorine, was approved in China, from the former CSO of Sunway Biotech.

Panel Discussion: Selecting the Best Contract Manufacturing to Ensure Quality Product

Panel discussion to determine the best strategies for choosing and working with contract manufacturing organisations to maximise efficiency while reducing cost.

The 2018 Summit will be held at the Hilton Back Bay Hotel, located near Cummings Park Business Center.

For more information visit Hilton Boston Back Bay website

58479498
Pool
Conference room
Area

CONFERENCE PACKAGES

AVAILABLE GROUP DISCOUNTS:

BOOK A TEAM OF 3 - Save and Additional 10%

BOOK A TEAM OF 4 - Save and Additional 15%

BOOK A TEAM OF 5+ - Save and Additional 20%

INTERESTED IN BECOMING A PARTNER?

MEET OUR PARTNERS

EXPERTISE PARTNER

EVENT PARTNER